Abstract
The aim of the study was to examine the effects of a mucolytic drug, carbocisteine, on rhinovirus (RV) infection in the airways. Human tracheal epithelial cells were infected with a major-group RV, RV14. RV14 infection increased virus titres and the cytokine content of supernatants. Carbocisteine reduced supernatant virus titres, the amount of RV14 RNA in cells, cell susceptibility to RV infection and supernatant cytokine concentrations, including interleukin (IL)-6 and IL-8, after RV14 infection. Carbocisteine reduced the expression of mRNA encoding intercellular adhesion molecule (ICAM)-1, the receptor for the major group of RVs. It also reduced the supernatant concentration of a soluble form of ICAM-1, the number and fluorescence intensity of acidic endosomes in the cells before RV infection, and nuclear factor-kappaB activation by RV14. Carbocisteine also reduced the supernatant virus titres of the minor group RV, RV2, although carbocisteine did not reduce the expression of mRNA encoding a low density lipoprotein receptor, the receptor for RV2. These results suggest that carbocisteine inhibits rhinovirus 2 infection by blocking rhinovirus RNA entry into the endosomes, and inhibits rhinovirus 14 infection by the same mechani...Continue Reading
Citations
Jul 17, 2013·Archives of Pharmacal Research·Mutsuo YamayaRyoichi Nagatomi
Oct 31, 2006·Oncogene·T D Gilmore, M Herscovitch
Jan 16, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Hisashi NogawaShigeki Matsuzawa
Aug 12, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Motoki YoshidaMutsuo Yamaya
Sep 3, 2010·Respirology : Official Journal of the Asian Pacific Society of Respirology·Li SunJian Kang
Sep 12, 2012·Pulmonary Medicine·Mutsuo Yamaya
Oct 25, 2011·PloS One·Lan JornotThierry Rochat
Apr 13, 2013·Cell Stress & Chaperones·Elisabetta PaceMark Gjomarkaj
Apr 14, 2012·Drug Metabolism Reviews·Steve C Mitchell, Glyn B Steventon
Nov 15, 2011·Respiratory Physiology & Neurobiology·Masanori AsadaMutsuo Yamaya
Oct 14, 2010·European Journal of Pharmacology·Mutsuo YamayaRyoichi Nagatomi
Apr 28, 2009·Respiratory Physiology & Neurobiology·Masanori YasuoKeishi Kubo
Nov 6, 2007·Journal of the American Geriatrics Society·Koichiro TatsumiUNKNOWN PEACE Study Group
Mar 22, 2016·Acta Pharmacologica Sinica·Wei WangNan-Shan Zhong
Sep 6, 2011·Journal of Medical Microbiology·Tomoko SumitomoShigetada Kawabata
Feb 22, 2012·Current Opinion in Pharmacology·Irfan Rahman, William MacNee
Dec 17, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Yun SongYong-Yao Cui
Nov 22, 2011·Biochimica Et Biophysica Acta·Irfan Rahman
Dec 24, 2014·International Immunopharmacology·Wei WangNan-Shan Zhong
Apr 11, 2015·PloS One·Luong Thi My NganYoung Joon Ahn
Mar 4, 2008·Journal of Neural Engineering·Dara FeiliThomas Stieglitz
Jun 16, 2012·Expert Review of Clinical Pharmacology·Irfan Rahman, Vuokko L Kinnula
Jun 13, 2012·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yuji IshibashiAkiyoshi Taniguchi
Jun 25, 2019·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Stephen C Mitchell, Glyn B Steventon
Jul 2, 2015·The Journal of Pharmacology and Experimental Therapeutics·Tomohiro ShinyaKeizo Sato
Jun 15, 2010·American Journal of Physiology. Lung Cellular and Molecular Physiology·Mutsuo YamayaRyoichi Nagatomi
Dec 14, 2016·Immunity, Inflammation and Disease·Mutsuo YamayaTetsuaki Kawase
Jul 28, 2018·Viruses·Olga A KhomichAlexander V Ivanov